# EU approves Enhertu with pertuzumab as first-line treatment for HER2-positive breast cancer

Canonical page: https://technooptimist.io/stories/eu-approves-enhertu-with-pertuzumab-as-first-line-treatment-for-her2-55bde3b5
Date: 1 Sep 2026
About: [Daiichi Sankyo](https://technooptimist.io/companies/daiichi-sankyo.md) · [Enhertu](https://technooptimist.io/biotech/enhertu.md)
Original source: https://www.biospace.com/press-releases/enhertu-plus-pertuzumab-approved-in-the-eu-as-first-new-regimen-in-more-than-a-decade-for-first-line-treatment-of-patients-with-her2-positive-metastatic-breast-cancer

The European Union approved Enhertu combined with pertuzumab as a first-line treatment for adults with HER2-positive metastatic breast cancer, based on the Phase III DESTINY-Breast09 trial. The combination cut the risk of progression or death by 44% against the standard THP regimen.

## Key facts

- Hazard ratio 0.56 (95% CI 0.44 to 0.71) versus THP.
- Median progression-free survival 40.7 months versus 26.9 months.
- The trial enrolled 1,157 patients overall; 383 were in the hazard ratio analysis.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.